ZOVIRAX is the brand name for acyclovir, a synthetic nucleoside analogue active against herpesviruses. ZOVIRAX Cream 5% is a formulation for topical administration.
ZOVIRAX Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older).
Media Articles Related to Zovirax Topical (Acyclovir Topical)
Cold Sores (Nongenital Herpes Simplex Infections)
Source: MedicineNet Ganglion Specialty [2015.02.18]
Title: Cold Sores (Nongenital Herpes Simplex Infections)
Category: Diseases and Conditions
Created: 6/16/1999 12:00:00 AM
Last Editorial Review: 2/18/2015 12:00:00 AM
Published Studies Related to Zovirax Topical (Acyclovir Topical)
Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. [2009.03]
BACKGROUND: Treatment of herpes simplex labialis (HSL) has been associated with modest benefits. This difficulty results from the rapid resolution of the disease accomplished by the immune system, which narrows the window of therapeutic opportunity. The immune response is also responsible for important clinical manifestations, including oedema and pain. The dual role of immune responses (protection, pathology) is well recognized in other infectious diseases. The addition of corticosteroids to antimicrobial agents has been associated with improvement in some of these diseases. OBJECTIVE: We evaluated the combination of oral valacyclovir plus topical clobetasol compared to placebo for recurrent HSL... CONCLUSIONS: This pilot study supports the addition of topical corticosteroids to an oral antiviral agent for the treatment of HSL. Larger studies need to confirm the safety and efficacy of this approach.
Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. 
OBJECTIVE: To compare silica gel with acyclovir cream in the treatment of recurrent herpes labialis... CONCLUSIONS: Silica gel was as effective in the treatment of recurrent herpes labialis as acyclovir and equally well tolerated and tended to take effect more quickly. Therefore, silica gel could prove a useful alternative to topical acyclovir.
A random clinical trial study to assess the efficiency of topical applications of podophyllin resin (25%) versus podophyllin resin (25%) together with acyclovir cream (5%) in the treatment of oral hairy leukoplakia. [2007.01]
OBJECTIVE: The objective of this study was to assess the efficiency of topical applications of podophyllin resin (25%) (P) versus podophyllin resin (25%) together with acyclovir cream (5%) (PA) in the treatment of oral hairy leukoplakia (OHL) in accordance with the following criteria: (1) number of applications necessary for the total clinical resolution of OHL; (2) correlation between the decrease of lesion size and the number of applications; (3) total clinical resolution of OHL; and (4) clinical reevaluation 12 months after the end of treatment... CONCLUSIONS: The present study demonstrated the following: (1) P and PA topical treatments presented a similar average number of applications performed weekly; (2) both groups showed the same clinical response at 12 months post-therapy; and (3) PA presented a 100% clinical resolution and a continuous decrease in OHL size over the course of weekly applications.
Topical iontophoretic administration of acyclovir for the episodic treatment of herpes labialis: a randomized, double-blind, placebo-controlled, clinic-initiated trial. [2006.08.15]
BACKGROUND: Multiple studies of the use of acyclovir for the treatment of herpes labialis have suggested that the nominal efficacy of the topical formulation is the result of inadequate penetration of the drug into the target site of infection, the basal epidermis... CONCLUSIONS: Single-dose topical iontophoresis of acyclovir appears to be a convenient and effective treatment for cold sores and merits further clinical investigation.
Role of acyclovir gel in herpes simplex: clinical implications. [2003.07]
CONCLUSIONS: The results demonstrate that a five-fold reduction in the ACY content in liposomal gel is sufficient for the complete healing of herpetic lesions in HSV-1 and HSV-2 infection. The increased duration of topical therapy may be acceptable for patients suffering from mild herpetic lesions because of the advantage of avoiding systemic and local side effects
Clinical Trials Related to Zovirax Topical (Acyclovir Topical)
Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2) [Completed]
The purpose of this study is to determine whether acyclovir is effective in suppressing HIV
viral load in women infected with both HIV-1 and herpes simplex virus type 2 (HSV-2) who are
starting HIV treatment for the first time.
Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV [Completed]
To compare the effect of high-dose valacyclovir (1 gram orally twice daily) versus
standard-dose acyclovir (400 mg orally twice daily) on the frequency of genital HSV
reactivation and on plasma HIV-1 levels among HSV-2/HIV-1 co-infected individuals. The
investigators hypothesize that high-dose valacyclovir will result in greater reduction in
plasma HIV-1 and genital HSV reactivation.
Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease [Recruiting]
Meniere's disease is a chronic illness that affects a substantial number of patients every
year worldwide. The disease is characterized by intermittent episodes of vertigo lasting
from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural
pressure. It has recently been suggested that viral etiologies specially Herpes virus might
be the underlying reason. The investigators study is a randomized, double- blinded
placebo-controlled clinical trial in Amiralam Hospital. In this study the primary objective
is to assess efficacy of Acyclovir in control of symptoms in patients with Meniere's disease
specially their vertigo attacks. Inclusion criteria would be patient's willingness to
participate in the study and follow ups, being 18 years old or older, having at least 2
vertigos per month each at least 20 min, interfering with function, and not on medication
for Meniere's disease for at least 3 months before the trial. They should not have any
history of allergy to Acyclovir, renal insufficiency or Creatinine above 1. 5 mg/dl, hepatic
enzymes more than three times normal, serious uncontrolled illness, be pregnant or nursing
or have previous surgeries on Endolymphatic Sac. Participants will be randomly placed in 2
different arms getting either Acyclovir 400 mg or placebo (inert ingredient). They will take
the medication for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a
day for the last 10 days. Patients will report changes in their symptoms 10 days after
initiating the drug and in 1, 3, 6 month intervals.
HSV-2 Shedding Resolution After Acyclovir Treatment [Completed]
The purpose of the study is to evaluate the pattern of viral shedding after beginning
treatment with acyclovir for a clinical recurrence of genital herpes and to compare it with
the pattern of viral shedding during an untreated clinical recurrence of genital herpes.
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth [Completed]
The purpose of this study is to test whether long-term treatment with oral acyclovir
improves the outcome for infants with herpes simplex virus (HSV) disease of the skin, eyes,
and mouth (SEM). Study participants will include infants in the United States and Canada who
have HSV disease of the skin, eyes, and mouth, with no central nervous system disease
present. Initially, all subjects will be treated with acyclovir administered through IV
access (through the vein) for 14 days while hospitalized. Participants will then be placed
in one of two groups, acyclovir given by mouth or a placebo (substance with no medication
present). The participant and the study site will not know to which group the subject is
assigned. All children will be followed at 6, 12, 24, 36, 48, and 60 months of age. During
the follow up visits, physicals, hearing assessments, eye assessments, and neurological
assessments will be completed.
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Zovirax Topical has an overall score of 7. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Zovirax Topical review by 25 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Shingles|
|Dosage & duration:|| || 5% cream (dosage frequency: applied as a cream 3 times a day) for the period of 1 week|
|Other conditions:|| || None|
|Other drugs taken:|| || Calomine Lotion + Pireteze anti histamine tablets|
|Benefits:|| || taken at a stage where puss filled blisters were swollen, ensured a quick and painless transition from this stage to a stage where blisters became dry. Not much effect for 5 days or so, however when the blisters did dry up they did so quickly and was not painful at all which is what i had expected. fairly easy to apply and good consistency for application.|
|Side effects:|| || None|
|Comments:|| || applied directly onto affected area 3 times a day. chose to apply generously and cover effected area with a bandage.|
Page last updated: 2015-02-18